QUOTE AND NEWS
TheStreet.com  Dec 11  Comment 
NEW YORK (TheStreet) -- Shares of Ariad Pharmaceuticals are down 2.85% to $6.82 in pre-market trading after Credit Suisse downgraded the global oncology company to "underperform" from "neutral" and lowered its price target to $6 from $8....
TheStreet.com  Dec 11  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES AbbVie was downgraded at Morgan Stanley to equal-weight from overweight. Twelve-month price target is $72. Stock is already pricing in potential for Hepatitis-C and Humira, Morgan Stanley said. Alico ...
Benzinga  Dec 11  Comment 
In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from Neutral to Underperform, and lowered the price target from $8.00 to $6.00. In the report, Credit Suisse noted,...
Benzinga  Dec 9  Comment 
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced safety and efficacy follow-up data on Iclusig^® (ponatinib), its approved BCR-ABL inhibitor, in patients with a baseline T315I mutation from its Phase 1 and Phase 2 PACE trials in...
Benzinga  Dec 8  Comment 
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig^® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid...
Motley Fool  Dec 5  Comment 
Ariad Pharmaceuticals shoots higher in November after its lead drug gets approved in a key overseas market, and following a generally favorable third-quarter earnings report.
Benzinga  Nov 6  Comment 
In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating and $8.00 price target on Ariad Pharmaceuticals (NASDAQ: ARIA). In the report, Credit Suisse noted, “Iclusig sales increased modestly in the US and...
newratings.com  Oct 27  Comment 
WASHINGTON (dpa-AFX) - Shares of Ariad Pharmaceuticals Inc. (ARIA) have gained more than 60 percent in the last one year, and it looks like the company is slowly getting back in the game. Here's the story of the fall and recovery...
Forbes  Oct 27  Comment 
Investors considering a purchase of ARIAD Pharmaceuticals, Inc. (NASD: ARIA) shares, but cautious about paying the going market price of $5.63/share, might benefit from considering selling puts among the alternative strategies at their disposal....




 

Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.





References

Morningstar.com

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki